metformin / Generic mfg. - LARVOL DELTA

Effect of metformin on pancreatic neuroendocrine tumors of multiple endocrine neoplasia type 1. (PubMed, J Neuroendocrinol) - "These findings indicate that, under the dosing and exposure conditions examined, metformin was not associated with measurable tumor-protective or tumor-preventive effects in MEN1-related PNETs. The study highlights important methodological considerations, including exposure timing and statistical power, and supports the need for prospective studies initiating metformin prior to tumor development in genetically predisposed populations."

Journal • Retrospective data • Diabetes • Gastrointestinal Neuroendocrine Tumor • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • Type 2 Diabetes Mellitus • MEN1

Antidiabetic effects of Gymnema sylvestre and metformin co-therapy in a type 2 diabetic rat model. (PubMed, World J Exp Med) - "This study demonstrated that metformin and GS, individually and in combination, improved glycemic control and metabolic outcomes in T2DM rats. While metformin showed the greater efficacy, combination therapy provided additive benefits, supporting GS as a potential adjunct in T2DM management."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug-drug interactions of antidepressant ammoxetine mediated by cytochrome P450 2D6 and multidrug and toxin extrusion protein 1: From in vitro mechanistic investigations to in vivo validation. (PubMed, J Pharmacol Exp Ther) - "In humanized liver mice, quinidine coadministration increased AMT exposure (AUCRobs = 2.87); in rats, AMT coadministration elevated metformin (MATE1 substrate) area under the curve by 68%...SIGNIFICANCE STATEMENT: This study reveals that the novel antidepressant ammoxetine poses dual drug interaction risks as a cytochrome P450 2D6 (CYP2D6) substrate/inhibitor affecting metabolism and a multidrug and toxin extrusion protein 1 inhibitor impairing renal excretion. Using humanized models and static mechanistic models, the interactions were validate in vivo and characterize the proposed metabolism-transport interaction cascade, delineating clinically relevant risks, including amplified ammoxetine exposure with strong CYP2D6 inhibition and heightened vulnerability in CYP2D6 poor metabolizers."

Journal • Preclinical • CNS Disorders • Depression • Oncology • Psychiatry • SLC22A1

Digital twin technologies for supporting self-care in adults with diet-related chronic conditions: a systematic review. (PubMed, Int J Med Inform) - "Two retrospective studies found substantial reductions in antidiabetic medication use, with one reporting a 74% reduction over one year including discontinuation of insulin in 94% of baseline insulin users, and large class‑specific declines, such as sulfonylureas (-99%) and DPP‑4 inhibitors (-88%), with many participants maintaining HbA1c < 7% on no therapy or metformin monotherapy, and the other showing that 42.8% of participants eliminated all diabetes medications within 90 days while maintaining glycaemic control (via a staged medication‑reduction framework)...Another study found that personalised insulin infusion guided by a DT over 14 days reduced insulin doses by 14-29% and increased time in the target glucose range to 86-97% (personal insulin pump data over a 14‑day collection period) DT-based interventions demonstrated potential to enhance multi-behavioural self-care and clinical outcomes in adults with type 2 diabetes. Evidence is..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Diabetic ketoacidosis in patients with type 2 diabetes: Risk factors for mortality and adverse outcomes. (PubMed, World J Exp Med) - "DKA carries a serious risk of mortality in both the short and long term in T2DM patients. Factors such as older age, dementia, PVD, CHF, low eGFR define the riskiest groups. These groups of patients may benefit from closer follow-up and more aggressive metabolic and comorbidity management after discharge."

Adverse events • Journal • Alzheimer's Disease • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Congestive Heart Failure • Dementia • Diabetes • Heart Failure • Immunology • Metabolic Disorders • Peripheral Arterial Disease • Pulmonary Disease • Respiratory Diseases • Type 2 Diabetes Mellitus • Vascular Neurology

Comment on "Association Between Metformin Usage and Vitamin B12 Deficiency Among Type 2 Diabetes Mellitus Patients at a Tertiary Care Center". (PubMed, Clin Med Insights Endocrinol Diabetes) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. (PubMed, Diabetes Obes Metab) - P3 | "Sitagliptin/empagliflozin FDC doses achieved improvements in glycaemic control at 24 weeks, which was maintained through 52 weeks. These benefits were accompanied by a favourable safety profile, including a very low risk of hypoglycaemia."

Journal • P3 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Persistence of fixed-dose combinations including dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes in Japan: analysis using a claims database. (PubMed, Expert Opin Pharmacother) - "Participants with T2D were receiving DPP-4i-based FDC treatments: DPP-4i/sodium-glucose cotransporter-2 inhibitor (SGLT2i), DPP-4i/metformin (met), DPP-4i/thiazolidinedione (TZD)...Discontinuation or switching to another drug class was more likely among older patients or those with comorbidities, including metastatic cancer and congestive heart failure. This real-world evaluation of FDC treatment in Japanese patients with T2D provides new insights into current practice."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus

Metformin Attenuates Osteoarthritis Progression by Modulating Mitochondrial Dynamics via Activation of the AMPK/Drp1 Pathway. (PubMed, J Inflamm Res) - "This study demonstrates that metformin delays osteoarthritis progression by activating the AMPK/Drp1 pathway to modulate mitochondrial fission and mitophagy, attenuate oxidative stress, and restore chondrocyte function. These findings provide novel mechanistic insight into the therapeutic potential of metformin in osteoarthritis and highlight mitochondrial dynamics as a promising target for future OA interventions."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • IL1B

Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study. (PubMed, J Gynecol Obstet Hum Reprod) - "Overall, biomarkers of oxidative stress improved in the metformin-only, melatonin, and sildenafil groups, suggesting that these drugs may have protective effects in PCOS patients. However, further studies are needed to determine their effectiveness."

Journal • Metabolic Disorders • Polycystic Ovary Syndrome

The WATCH-DM integer-based risk score identifies risk of all-cause mortality in patients with type 2 diabetes: a retrospective cohort study. (PubMed, Ther Adv Endocrinol Metab) - "Metformin use was independently associated with lower mortality risk (HR: 0.410, p = 0.019). The WATCH-DM(i) score is a robust prognostic marker of 5-year all-cause mortality in T2DM patients without HF and may serve as a practical tool for risk stratification in outpatient settings."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Synergistic induction of apoptosis by the epigenetic modulator decitabine and metformin in gastric cancer cells highlights the potential for combination therapy. (PubMed, Sci Rep) - No abstract available

Journal • Gastric Cancer • Oncology • Solid Tumor

Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (clinicaltrials.gov) - P4 | N=186 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P4 trial • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

UNDERSTANDING THE IMPLEMENTATION OF SICK DAY MEDICATION GUIDANCE BY HEALTH CARE PROFESSIONALS: A SURVEY EVALUATION (ISN-WCN 2026) - "Certain medications increase the risk of AKI during acute illness, including sulfonylureas, angiotensin converting enzyme inhibitors (ACEi), diuretics, metformin, angiotensin receptor blockers (ARBs), non-steroidal anti-inflammatories drugs (NSAIDS), and sodium glucose co-transporter 2 (SGLT2) inhibitors (SADMANS medications)...Addressing these challenges through clearer workplace guidelines, multidisciplinary coordination and tailored educational materials are needed to embed SDMG into routine care. Further research is also needed to evaluate real-world outcomes of providing SDMG to better support uptake."

Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Renal Disease

RENAL CYTOKINE PROFILE IMPROVEMENT WITH SGLT2 INHIBITORS IN ALBUMINURIC DIABETIC KIDNEY DISEASE (ISN-WCN 2026) - "At baseline, eGFR was 52 mL/min/1.73m2, median albuminuria was 838 mg/g (59.9% A3), BMI 30.1 kg/m2, and HbA1c 6.8%; 83% were on ACEi/ARB, 63.8% on metformin, 26.8% on GLP-1 RA, and 27.8% on insulin. Dapagliflozin was started in 68 patients and empagliflozin in 4...She has received travel and congress fees support from Astra-Zeneca, Esteve, NovoNordisk, Boehringer-Ingelheim Lilly, Astellas, Otsuka, Novartis, Bayer, Alexion, GSK, and Baxter. She has participated in advisory boards adn scientific lectures organized by Astra-Zeneca, Boehringer-Ingelheim Lilly, Otsuka, Esteve, Mundipharma, NovoNordisk, Astellas, Novartis, Bayer, Alexion, GSK, Roche, and Baxter.I did not use generative AI and AI-assisted technologies in the writing process."

Chronic Kidney Disease • Diabetic Nephropathy • Inflammation • Nephrology • Renal Disease • CCL8 • CSF2 • CXCL10 • CXCL11 • CXCL8 • CXCL9 • IFNG • IL10 • IL13 • IL15 • IL18 • IL1B • IL2 • IL4 • IL6 • IL7

OPEN-MINDEDNESS IN TEACHING THE RENAL SYSTEM: INTEGRATING BAYESIAN REASONING, AND AI IN EDUCATION (ISN-WCN 2026) - "Views on T2DM differed: local colleagues emphasized metformin, while overseas educators referenced newer evidence on remission through weight loss, bariatric surgery, or GLP-1 receptor agonists/SGLT2 inhibitors...Such an approach better prepares the community for evolving clinical realities and cultivates adaptability in future healthcare providers. More shall be discussed during the presentation."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFECT OF ONCE-WEEKLY SEMAGLUTIDE 1.0 MG ON KIDNEY OUTCOMES BY BASELINE CHARACTERISTICS: EXPLORATORY DATA FROM THE FLOW TRIAL (ISN-WCN 2026) - P3 | "A considerable proportion of participants were receiving metformin (51.9%) and insulin (61.4%) at baseline.The benefit of semaglutide on the 4-component kidney-specific composite outcome was consistent across most baseline subgroups including sex (interaction p value [pint]=0.1557), race (pint= 0.4812), HbA1c (pint=0.4941), retinopathy status (pint=0.4927) and diuretic use (pint=0.2503) (Fig). No heterogeneity was observed for the effect of semaglutide on kidney failure across any of the baseline subgroups.Conclusion In the FLOW trial, the benefit of semaglutide on key kidney outcomes was generally consistent across baseline subgroups, with the exception of diabetes duration 15 years which requires further study.Download: Download high-res image (361KB)Download: Download full-size imageFigure. Subgroup analyses of the 4-component, kidney-specific composite outcome by baseline characteristics."

Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Retinal Disorders

THE IMPACT OF COMPREHENSIVE MEDICATION MANAGEMENT ON CLINICAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (ISN-WCN 2026) - "In the IG, SGLT2 inhibitor use increased from 36.2% to 63.8% (p<0.001) and metformin use from 38.3% to 55.3% (p=0.011)...The absence of significant eGFR changes likely reflects the limited duration of follow-up. These findings support the broader adoption of CMM to improve comprehensive chronic disease management."

Clinical • Clinical data • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hypertension • Metabolic Disorders • Nephrology • Pulmonary Arterial Hypertension • Renal Disease • Type 2 Diabetes Mellitus

INCREASE IN METFORMIN–ASSOCIATED LACTIC ACIDOSIS IN A TERTIARY CROATIAN HOSPITAL AFTER THE COVID PANDEMIC (ISN-WCN 2026) - "MALA incidence increased notably during the pandemic but began to decline in 2024 as the healthcare system adapted to post-COVID-19 conditions. Sustained vigilance and patient-centered care are necessary to prevent recurrence of such adverse trends."

Clinical • Cardiovascular • Diabetes • Hepatology • Hypoglycemia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease • Septic Shock • Type 2 Diabetes Mellitus

EXPLORING SICK DAY MANAGEMENT IN CULTURALLY AND LINGUISTICALLY DIVERSE PATIENTS WITH CHRONIC KIDNEY DISEASE (ISN-WCN 2026) - "These medications include sulfonylureas, angiotensin-converting enzyme (ACE) inhibitors, diuretics, metformin, angiotensin receptor blockers (ARBs) nonsteroidal anti-inflammatory drugs (NSAIDs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors (SADMANS)...Although many participants actively manage their health to avoid getting sick (n=71, 94.7%) and believed they could effectively manage their illness by themselves when unwell (n=57, 76.0%), most did not know what medication(s) to stop when unwell (n=40, 54.8%) and therefore would normally contact their GP when unwell (n=67, 89.3%).Conclusion Patients of CALD background showed willingness to manage their health when acutely unwell but lacked practical knowledge and resources like sick day action plans. Better SDMG provision can enable patients to safely and effectively self-manage their medications during acute illness."

Clinical • Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Renal Disease

SEVERE HYPOMAGNESEMIA IN A DIABETIC PATIENT ON MULTIPLE LONG-TERM MEDICATIONS (ISN-WCN 2026) - "Vonoprazan, metformin, and semaglutide were discontinued, and intravenous magnesium and calcium supplementation was initiated with concomitant oral alfacalcidol...Vonoprazan was replaced with famotidine...Following withdrawal of the causative drugs and magnesium repletion, both magnesium and calcium levels normalized promptly and remained stable thereafter.Conclusion In diabetic patients on long-term polypharmacy, clinicians should be alert to drug-induced hypomagnesemia. Regular and long-term monitoring of serum magnesium is essential, particularly in those receiving medications that may alter intestinal absorption or hormonal regulation of magnesium homeostasis."

Clinical • Anorexia • Diabetes • Endocrine Disorders • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

Development and Evaluation of a Baicalin-Loaded Phytosomal Transdermal Patch for Type 2 Diabetes Mellitus. (PubMed, Curr Drug Metab) - "The developed phytosomal transdermal patch showed sustained release, better permeation, and potent antidiabetic activity; thus, it offers an alternative to conventional T2DM therapies."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease. (PubMed, Exp Eye Res) - "These data identify PDGFβ-mediated AMPK suppression as a pathogenic mechanism in TED fibroblasts and demonstrate that AMPK reactivation reduces pro-fibrotic and inflammatory signals. Together, these findings support the therapeutic repurposing of metformin in TED."

Journal • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease • CXCL8 • IL6

Metformin-induced encephalopathy in a peritoneal dialysis patient: the critical role of hemodialysis in reversing lentiform fork sign: a case report. (PubMed, BMC Neurol) - No abstract available

Journal • Chronic Kidney Disease • CNS Disorders • Nephrology • Renal Disease

Ocimum tenuiflorum L. extracts attenuate polycystic ovarian syndrome in letrozole treated female Wistar rats through modulation of iNOS, COX-2, IL-1β and TNF-α. (PubMed, J Mol Histol) - "After induction (21 days), the rats received oral treatment with methanol (OTM) and ethyl acetate (OTEA) extracts of Ocimum tenuiflorum at the dose of 50 and 100 mg/kg body weight, while metformin (25 mg/kg body weight) was used as the positive control. Finally, GC-MS analysis confirmed the active compounds with robust anti-inflammatory efficacy. Our study showed that Ocimum tenuiflorum has the potential to attenuate PCOS by restoring hormonal levels and exerting anti-inflammatory effects."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Infertility • Polycystic Ovary Syndrome • Sexual Disorders • IL1B • TNFA